About Us
Based in Dublin, RemedyBio is a nano scale biotechnology company pioneering ultra high throughput therapeutic discovery.
Our mission is to create new therapies for the world’s most challenging diseases by mapping the function of cells directly from patient biology, harnessing the power of the human immune system to cure disease.
Leadership Team
He serves on the board of the AMBER Centre for Advanced Materials and Bioengineering Research headquartered at Trinity College Dublin. Dan holds a BA and MSc from Trinity College Dublin, a PDip from Oxford University, received his MBA from Cornell where he was an Angear Merit Scholar, and is a Kauffman Fellow.
Dr. Leach holds a B.S. degree in Biology from Hillsdale College, a Ph.D. in Molecular Biology from Ohio University, was a Fellow in the Division of Experimental Therapeutics at Walter Reed Army Institute of Research for the US Department of Defense and was a Visiting Fellow at the National Cancer Institute of the National Institutes of Health.
Colm holds medical and MSc degrees from Trinity, as well as an MBA from UCD’s Smurfit Business School. He is a Fellow of the Faculty of Pharmaceutical Medicine (RCP UK). Colm is an active member of PKU Ireland and a former IPPOSI board member.
Isabel holds a PhD in Diagnostics and Therapeutics from the Royal College of Surgeons in Ireland, a B.A. (Mod) in Biochemistry from Trinity College Dublin and studied Chemical Engineering at the University of Valladolid in Spain.
Scientific Advisory Board
Dr. Miller has also collaborated significantly with leading academic research teams and is recognized as an effective thought-leader and champion for genomics and genetics-driven target and drug discovery. He has a deep knowledge of exploratory biology, target hunting, target validation, and translational research in multiple disease areas. He has worked extensively in developing and applying technologies to assess gene and protein function in highly translational model systems.
Dr. Miller holds a Ph.D. in Pharmacology from Michigan State University and completed post-doctoral training in Molecular Endocrinology at the Massachusetts General Hospital in Boston. He has recently joined RemedyBio's Scientific Advisory Board, where his expertise in target and discovery will be critical in helping the company choose new effective precision therapies for the treatment of cancer.